SCHEMBL9924422

SCHEMBL9924422

O=C(/N=C(/Nc1cccc(Cl)c1)N[C@H]1CC[C@H](Nc2ncccn2)CC1)c1ccc(F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
MCHR1 Q99705 8/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.41
EPHX1 P07099 1/20 0.41
TSHR P16473 1/20 0.41
EPHX2 P34913 1/20 0.41
RAB9A P51151 1/20 0.41
CES1 P23141 1/20 0.40
GRM5 P41594 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
HTR2B P41595 1/20 0.39
NPY5R Q15761 1/20 0.39
CSNK2A2 P19784 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206687 0.91 KCNQ3 (0.45) KCNQ3KCNQ2MEN1KMT2ALMNA
SCHEMBL9924233 0.91 KMT2A (0.49) KCNQ3KCNQ2MCHR1MEN1KMT2A
SCHEMBL17206691 0.90 KCNQ3 (0.41) KCNQ3KCNQ2MCHR1MEN1KMT2A
SCHEMBL9901952 0.90 KCNQ3 (0.41) KCNQ3KCNQ2MCHR1MEN1KMT2A
SCHEMBL9900854 0.90 KCNQ3 (0.41) KCNQ3KCNQ2MCHR1MEN1KMT2A
SCHEMBL9900852 0.90 KCNQ3 (0.41) KCNQ3KCNQ2MCHR1MEN1KMT2A
SCHEMBL9924419 0.90 KCNQ3 (0.41) KCNQ3KCNQ2MCHR1MEN1KMT2A
SCHEMBL9924143 0.89 EPHX2 (0.44) KCNQ3KCNQ2MCHR1MEN1KMT2A
SCHEMBL9924260 0.87 MEN1 (0.46) MEN1KMT2ALMNANPC1EPHX1
SCHEMBL17206628 0.86 MEN1 (0.45) MEN1KMT2ALMNANPC1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed